MaxCyte, Inc. (LON:MXCT - Get Free Report) insider John Johnston sold 5,000 shares of the company's stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of GBX 441 ($5.54), for a total value of £22,050 ($27,680.14).
MaxCyte Stock Performance
Shares of MXCT stock opened at GBX 335 ($4.21) on Wednesday. The company has a debt-to-equity ratio of 8.07, a current ratio of 10.65 and a quick ratio of 14.38. MaxCyte, Inc. has a fifty-two week low of GBX 180 ($2.26) and a fifty-two week high of GBX 440 ($5.52). The stock's 50-day moving average is GBX 360.05 and its two-hundred day moving average is GBX 333.31. The firm has a market cap of £348.84 million, a P/E ratio of -1,141.38 and a beta of 1.04.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
